The new patent, number 7,851,506, is also listed in the US Food and Drug Administration’s Approved Drug Products List (the Orange Book).
In addition to the newly issued patent, Xyrem is protected by seven other patents related to the product’s formulation and Jazz Pharmaceuticals‘ distribution system.
Six issued patents are now listed in the Orange Book.
The patents expire from 2019 to 2024.
Jazz Pharmaceuticals chairman and CEO Bruce Cozadd said enhancing and enforcing the intellectual property coverage for Xyrem is an important strategic priority for our company.
Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry.